FMC Corp vs IDEXX Laboratories, Inc. — how do they compare? FMC Corp trades at $10.22 (market cap $1.30B), while IDEXX Laboratories, Inc. trades at $571.96 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 35.6× FMC Corp's market cap, and FMC Corp pays a 3.07% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| FMC | IDXX | |
|---|---|---|
Market Cap | $1.30B | $46.22B |
Sector | Basic Materials | Health |
52-Week High | $40.69 | $766.68 |
52-Week Low | $10.01 | $526.44 |
Enterprise Value | $5.11B | $47.12B |
Dividend Yield | 3.07% | — |
Signals from Pluang's Aura AI — not financial advice
FMC stock trades at $10.17, down 2.82% today, amid bearish technical signals and weak fundamentals. Recent Q2 2026 earnings beat estimates but revenue missed, with full-year guidance lowered. The company faces significant profitability challenges, with a net income margin of -84.83% and negative ROE/ROA. Positive developments include a $400 million minority investment from Tessenderlo Group and ongoing debt reduction efforts.
The outlook remains cautious due to persistent earnings pressure and high debt levels, though asset sales and external funding provide liquidity support. Analyst consensus is mixed with a $11.60 price target, suggesting modest upside potential if operational improvements materialize. Key risks include volatile cash flows, competitive pressures, and macroeconomic headwinds affecting agricultural demand.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Trailing returns across standard periods
Latest headlines on both assets
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →